• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Psoriasis Drug Skyrizi is Now Available as a Single Injection


Previously patients administered as two, 75-mg shots. Now they can inject a single 150-mg dose.

AbbVie’s Skyrizi (risankizumab-rzaa) is now available in the United States as a single-dose 150 mg injection for the treatment of adults with moderate-to-severe plaque psoriasis. Previously two 75-mg injections per dose, the 150 mg dosage is now administered with one injection per dose either with a prefilled pen or syringe every 12 weeks following two starter doses.

The new Skyrizi 150-mg pen incorporates wide grip handles, audible cues to help guide the administration process, and an indicator to signal when administration is complete.

The FDA approved Skyrizi 150 mg in April based on data from three clinical trials showing the single-dose 150 mg injection was bioequivalent to two injections of 75 mg per dose each.

“We know many people living with psoriasis are looking for flexibility in how they manage their disease,” Patrick Horber, president, U.S. Immunology at AbbVie, said in a statement. “That's why we're proud to provide an updated Skyrizi treatment experience that allows for fewer injections of the same Skyrizi that patients and providers have come to know and trust.”

Skyrizi is part of a collaboration between AbbVie and Boehringer Ingelheim.

Psoriasis affects more than 3% of the U.S. adult population, or about 7.5 million people.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.